🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07222410
Recruiting Not applicable

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

NCT07222410 · tracked via the Priya Life Science USA tracker
Sponsor
Fisher and Paykel Healthcare
Phase
Not applicable
Started
2026-01-07
Last updated
2026-06-23

Condition(s) studied

COPD

Investigational drug(s) / intervention(s)

Closed loop oxygen controlManual titration

Closed loop oxygen control: Nasal high flow with closed loop oxygen control

Manual titration: Nasal high flow with manual titration

Study summary

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Eligibility

Sex
ALL
Min age
22 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Has cognitive ability to provide informed consent * Aged 22 years or older * Hospitalized with hypoxemia/respiratory distress * Diagnosis of COPD * Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator * Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous) Exclusion Criteria: * Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines * Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support) * Patient receiving end of life care * Nasal or facial conditions precluding use of nasal high flow * Pregnancy or breastfeeding * Cognitive impairment or impaired consciousness precluding informed consent * Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator * Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included * The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator * Has already participated in this clinical trial

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
The University of Alabama at Birmingham Birmingham Alabama Recruiting
Central Iowa Hospital Corp - UnityPoint Health Des Moines Iowa Recruiting
Icahn School of Medicine at Mount Sinai New York New York Recruiting
Temple University Hospital Philadelphia Pennsylvania Recruiting

More Fisher and Paykel Healthcare trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07222410 on ClinicalTrials.gov ↗ ← All trials in the USA